Vutrisiran is a double-stranded small interfering RNA (siRNA) therapeutic indicated for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis. This RNA interference agent… Read more
Vutrisiran is a double-stranded small interfering RNA (siRNA) therapeutic indicated for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis. This RNA interference agent functions by silencing the expression of both wild-type and mutant transthyretin (TTR) proteins, thereby reducing the buildup of amyloid deposits in peripheral nerves. This category provides access to high-quality Vutrisiran reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for critical analytical testing, such as impurity profiling, method validation, and rigorous quality control protocols. By providing well-characterized reference materials, these compounds support the development and ongoing stability monitoring of complex oligonucleotide drug formulations, ensuring compliance with regulatory standards throughout the drug lifecycle.